Information: This is an outdated version of the data model. You can find a Versions overview via Versions on the left. You can find the newest Version by clicking here.
Information:
Error:
ID
34430
Description
A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification; ODM derived from: https://clinicaltrials.gov/show/NCT02468661
Link
https://clinicaltrials.gov/show/NCT02468661
Keywords
Versions (3)
- 1/17/19 1/17/19 -
- 4/20/20 4/20/20 -
- 4/25/20 4/25/20 -
Copyright Holder
see on clinicaltrials.gov
Uploaded on
January 17, 2019
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Non-Small Cell Lung Cancer NCT02468661
Eligibility Non-Small Cell Lung Cancer NCT02468661
- StudyEvent: Eligibility
Similar models
Eligibility Non-Small Cell Lung Cancer NCT02468661
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
ID.1
Item
locally advanced or metastatic nsclc
boolean
ID.2
Item
egfr mutation (l858r and /or ex19del)
boolean
ID.3
Item
cmet amplification by fish (gcn ≥ 6),
boolean
ID.4
Item
acquired resistance to egfr tki (1st or 2nd génération)
boolean
ID.5
Item
ecog performance status (ps) ≤ 1.
boolean
ID.6
Item
prior treatment with 3rd generation tki
boolean
ID.7
Item
phaseii : prior treatment with any of the following agents:
boolean
ID.8
Item
crizotinib, or any other cmet inhibitor or hgf-targeting inhibitor.
boolean
ID.9
Item
concomitant egfr tki and platinum based chemotherapy as first line regimen.
boolean
ID.10
Item
platinum-based chemotherapy as first line treatment
boolean